215 related articles for article (PubMed ID: 36091746)
1. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
Zhou D; Luo X; Zhou Z; Zeng X; Wan X; Tan C; Liu Q
Front Pharmacol; 2022; 13():880280. PubMed ID: 36091746
[No Abstract] [Full Text] [Related]
2. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China.
Gong J; Su D; Shang J; Xu S; Tang L; Sun Z; Liu G
Front Pharmacol; 2022; 13():830380. PubMed ID: 35614942
[No Abstract] [Full Text] [Related]
5. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Luo X; Zhou Z; Zeng X; Liu Q
Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
Cheng R; Zhou Z; Liu Q
Cancer Med; 2023 Mar; 12(6):7389-7397. PubMed ID: 36373001
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
Qiao L; Zhou Z; Zeng X; Tan C
Front Pharmacol; 2021; 12():728440. PubMed ID: 34795580
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
[TBL] [Abstract][Full Text] [Related]
12. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China.
Liu Q; Luo X; Zhou Z; Peng L; Yi L; Wan X; Tan C; Zeng X
Front Oncol; 2021; 11():745493. PubMed ID: 34966668
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
15. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Shi F; He Z; Su H; Wang L; Han S
Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Liu Y; Shao R
Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.
Pei Z; Xiao N; Yang P
Front Pharmacol; 2023; 14():1265784. PubMed ID: 37964872
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
